TG 4010
Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010Latest Information Update: 23 Sep 2021
At a glance
- Originator Transgene
- Developer Bristol-Myers Squibb; Transgene; University of California, Davis
- Class Cancer vaccines; Membrane glycoproteins
- Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 13 Dec 2019 Discontinued - Phase-I for Prostate cancer in USA (IM)
- 13 Dec 2019 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA, Denmark, France, Belgium, Hungary (SC)
- 13 Dec 2019 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC)